Ultra High-Field (7T) Magnetic Resonance Spectroscopy (MRS) in people with Amyotrophic Lateral Sclerosis (ALS)

Nazem Atassi¹, Christina Triantafyllou¹, Boris Keil², Robert Lawson¹, Lindsay Kaplan¹, Christina Dheu¹, Alyssa Murphy¹, James Berry¹, Nouha Salibi², Ravi Seethamraju¹, Bruce Rosen³, Merit Cudkowicz¹, and Eva-Maria Ratai²

¹Neurology, Massachusetts General Hospital, Boston, MA, United States, ²Radiology, MGH/HST Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, United States, ³Siemens Healthcare, MR R&D, Siemens, Auburn, AL, United States, ⁴Siemens Healthcare, MR R&D, Siemens, Charlestown, MA, United States

Target Audience: Neurologists, Neuroradiologists, MR Physicist, MR Spectroscopists

Purpose: Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disorder that predominantly affects the upper and lower motor neurons. The etiology of ALS is not well understood but studies of the SOD1 rodent models of ALS suggest that glutamate excitotoxicity and neuroinflammation play an essential role in ALS progression. We studied brain metabolites changes that are related to these two mechanisms using ultra-high magnetic field (7-Tesla) magnetic resonance spectroscopy (MRS) in people with ALS.

Methods: A total of nine patients with ALS and seven age-matched healthy controls were enrolled in the study. Of the 16 subjects eight ALS subjects (7 male, 53y ± 9y) and six healthy controls (3 male, 55.5y ± 12y) had good quality MRS data that were included in the analysis. All subjects had to be considered medically safe to tolerate MRI. Subjects were required to have a vital capacity (VC) ≥ 50% at screening. Clinical measures included disease duration, revised ALS Functional Rating Scale (ALSFRS-R), vital capacity, and reflexes measurements.

Results: The comparison between ALS patient and healthy controls revealed a decrease (p=0.03) in NAA+NAAG/Cr in people with ALS compared to healthy controls (HC) (Figure 2). In addition, we identified whether changes in NAA+NAAG and/or Cr are responsible for the changes observed in the ratio, and found a decrease in NAA+NAAG (p=0.02) in people with ALS compared to HC and no differences in Cr (p = 0.21). Furthermore, we separated differences in NAA and NAAG between ALS and HC subject and found both metabolite concentrations to be decreased (P = 0.03 and P = 0.04, respectively). Glutamate (p = 0.03) as well as Glu/Cr (p = 0.003) were decreased in people with ALS compared to HC, while neither Gln (p = 0.6) nor Gln/Cr (p = 0.8) were altered in ALS. No difference in Cho/Cr was observed (p = 0.7). Interestingly, MI/Cr was increased in people with ALS compared to HC (p=0.1).

Furthermore, certain clinical outcomes were collected for each ALS subject to assess disease progression; these included Vital Capacity (VC 86% ± 20.6) ALSFRS (37 ± 4.9) Reflex total (23 ± 7.2) and time from diagnosis to scanner (17 months ± 18.4). We performed correlations between clinical measures and spectroscopic markers (Figure 3). MI/Cr was positively correlated with increased reflexes (R² = 0.80, p=0.02) and also Cho/Cr was positively correlated with increased reflexes (R² = 0.66, p=0.07).

Discussion: Our finding of decreased NAA/Cr in ALS is suggestive of neuronal loss in the motor cortex and is consistent with ALS pathology and previous 1.5T and 3T MRS studies in ALS. Contrary to our initial hypothesis, we saw a decrease in glutamate in the ALS group without significant changes in Glutamine. One of the limitations of MRS is the inability to differentiate intra- from extra-cellular metabolites changes, suggesting that the decrease in glutamate might be secondary to the loss of intracellular glutamate due to neuronal degeneration. Interestingly, we saw a trend for increased MI/Cr in the ALS group suggesting increased glial proliferation and inflammation in the motor cortex. Furthermore, the increase in MI/Cr strongly correlates with pathological reflexes, a clinical marker of upper motor neuron degeneration. In addition, Cho/Cr, another inflammatory marker correlates with pathological reflexes. These findings are consistent with the increase of activated microglia around motor neurons seen in ALS postmortem tissue and rodent pathological studies.

Conclusion: In conclusion, MRS is a promising tool to study molecular changes in people with ALS and longitudinal MRS studies are needed to better characterize these molecular changes as the disease progresses over time.

Acknowledgments: This study was funded by a pilot grant from Harvard NeuroDiscovery Center. The primary investigator received fellowship training grants from the American Academy of Neurology (AAN) and the Muscular Dystrophy Association (MDA).